Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · October 20, 2024

Outcomes of Using Hydroxychloroquine as an Adjuvant Therapy in Patients With Folliculitis Decalvans

Clinical and Experimental Dermatology

 

Additional Info

Clinical and Experimental Dermatology
Hydroxychloroquine may be beneficial as an adjuvant therapy for folliculitis decalvans: a 5-year retrospective study with 49 patients
Clin Exp Dermatol 2024 Sep 28;[EPub Ahead of Print], I Doche, MN Sotto, MK Hordinsky, IP Melhado, P Gerlero, MC Rivitti-Machado

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading